Reprieve Cardiovascular Secures $61 Million Financing and Enrolls First Patient in Pivotal Study

Reprieve Cardiovascular, Inc., a clinical-stage company pioneering intelligent decongestion management therapy for acute decompensated heart failure (ADHF), today announced the close of an oversubscribed $61 million Series B financing led by Deerfield Management and joined by Arboretum Ventures, Lightstone Ventures, Sante Ventures, Genesis Capital, Rex Health Ventures, and Cadence Capital, as well as an undisclosed strategic investor.